Guardant Health is a precision oncology company focused on helping conquer cancer through use of its proprietary tests, data sets and analytics. Co.'s Guardant Health Oncology Platform is designed to utilize its capabilities in technology, clinical development, regulatory and reimbursement. Co. engages in the clinical liquid biopsy market with its tests. Co.'s Guardant360 test is a molecular diagnostic test measuring cancer-related genes, and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. Co. has launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to address the need in Stage II-III colorectal cancer. The GH average annual return since 2018 is shown above.
The Average Annual Return on the GH average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GH average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free GH Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
